United Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension Research

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.

United Therapeutics Corp. is currently recruiting participants for the DeciPHer-ILD study, a real-world patient registry focused on Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). The study aims to gather comprehensive data on demographics, treatment patterns, and clinical outcomes to enhance understanding of the disease and its management. This observational study will follow patients over five years, providing valuable insights into the epidemiological landscape of PH-ILD.

The study involves three cohorts: patients not receiving inhaled treprostinil, those newly initiated on Tyvaso/Tyvaso DPI, and patients who have been on Tyvaso/Tyvaso DPI for over 60 days. These interventions aim to observe treatment effects and patient outcomes over time.

Designed as a prospective cohort study, DeciPHer-ILD will collect data through various assessments, including pulmonary function tests, imaging, and quality of life questionnaires. The study does not involve any masking and focuses on observational data collection.

The study began on January 23, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 8, 2025, indicating ongoing recruitment and data collection efforts.

This study could significantly impact United Therapeutics’ market position by providing critical data that may influence treatment approaches and patient outcomes. Investors may view this as a positive development, potentially boosting stock performance. Competitors in the pulmonary hypertension treatment market will likely monitor these developments closely.

The DeciPHer-ILD study is actively recruiting, with further details available on the ClinicalTrials portal.